BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11576847)

  • 1. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer.
    Einbeigi Z; Bergman A; Kindblom LG; Martinsson T; Meis-Kindblom JM; Nordling M; Suurküla M; Wahlström J; Wallgren A; Karlsson P
    Eur J Cancer; 2001 Oct; 37(15):1904-9. PubMed ID: 11576847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.
    Einbeigi Z; Bergman A; Meis-Kindblom JM; Flodin A; Bjursell C; Martinsson T; Kindblom LG; Wahlström J; Wallgren A; Nordling M; Karlsson P
    Fam Cancer; 2007; 6(1):35-41. PubMed ID: 16944270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
    Verhoog LC; van den Ouweland AM; Berns E; van Veghel-Plandsoen MM; van Staveren IL; Wagner A; Bartels CC; Tilanus-Linthorst MM; Devilee P; Seynaeve C; Halley DJ; Niermeijer MF; Klijn JG; Meijers-Heijboer H
    Eur J Cancer; 2001 Nov; 37(16):2082-90. PubMed ID: 11597388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.
    Bergman A; Flodin A; Engwall Y; Arkblad EL; Berg K; Einbeigi Z; Martinsson T; Wahlström J; Karlsson P; Nordling M
    Fam Cancer; 2005; 4(2):89-96. PubMed ID: 15951958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations.
    Borg A; Dørum A; Heimdal K; Maehle L; Hovig E; Møller P
    Dis Markers; 1999 Oct; 15(1-3):79-84. PubMed ID: 10595257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.
    Meindl A;
    Int J Cancer; 2002 Feb; 97(4):472-80. PubMed ID: 11802209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using gene carrier probability to select high risk families for identifying germline mutations in breast cancer susceptibility genes.
    Chang-Claude J; Dong J; Schmidt S; Shayeghi M; Komitowski D; Becher H; Stratton MR; Royer-Pokora B
    J Med Genet; 1998 Feb; 35(2):116-21. PubMed ID: 9507390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G.
    Claes K; Machackova E; De Vos M; Poppe B; De Paepe A; Messiaen L
    Dis Markers; 1999 Oct; 15(1-3):69-73. PubMed ID: 10595255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 mutations among Finnish ovarian carcinoma families.
    Sarantaus L; Auranen A; Nevanlinna H
    Int J Oncol; 2001 Apr; 18(4):831-5. PubMed ID: 11251181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.
    Vehmanen P; Friedman LS; Eerola H; McClure M; Ward B; Sarantaus L; Kainu T; Syrjäkoski K; Pyrhönen S; Kallioniemi OP; Muhonen T; Luce M; Frank TS; Nevanlinna H
    Hum Mol Genet; 1997 Dec; 6(13):2309-15. PubMed ID: 9361038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
    de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
    Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline BRCA1 mutation analysis in Indian breast/ovarian cancer families.
    Kumar BV; Lakhotia S; Ankathil R; Madhavan J; Jayaprakash PG; Nair MK; Somasundaram K
    Cancer Biol Ther; 2002; 1(1):18-21. PubMed ID: 12170759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a founder BRCA2 mutation in Sardinian breast cancer families.
    Monne M; Piras G; Fancello P; Santona MC; Uras A; Landriscina G; Mastio G; Gabbas A
    Fam Cancer; 2007; 6(1):73-9. PubMed ID: 17216544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and benefits of diagnosing familial breast cancer.
    Heimdal K; Maehle L; Møller P
    Dis Markers; 1999 Oct; 15(1-3):167-73. PubMed ID: 10595273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1.
    Lancaster JM; Carney ME; Gray J; Myring J; Gumbs C; Sampson J; Wheeler D; France E; Wiseman R; Harper P; Futreal PA
    Br J Cancer; 1998 Dec; 78(11):1417-20. PubMed ID: 9836472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
    Frank TS; Deffenbaugh AM; Hulick M; Gumpper K
    Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First BRCA1 and BRCA2 gene testing implemented in the health care system of Stockholm.
    Arver B; Borg A; Lindblom A
    Genet Test; 2001; 5(1):1-8. PubMed ID: 11336395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
    Chang-Claude J; Becher H; Caligo M; Eccles D; Evans G; Haites N; Hodgson S; Møller P; Weber BH; Stoppa-Lyonnet D
    Dis Markers; 1999 Oct; 15(1-3):53-65. PubMed ID: 10595253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.